Virtual Library

Start Your Search

Shunki Hirayama



Author of

  • +

    P3.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 982)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.16-25 - Impact of Diabetes Mellitus on Survival Outcome in Patients with Pathological Stage IA Non-Small Cell Lung Cancer (ID 12245)

      12:00 - 13:30  |  Presenting Author(s): Shunki Hirayama

      • Abstract
      • Slides

      Background

      The aim of this study was to investigate the impact of diabetes mellitus (DM) on prognosis of non-small cell lung cancer (NSCLC) patients with pathological stage IA.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      A retrospective study was performed on 506 patients with pathological stage IA in NSCLC, who underwent complete resection between 2008 and 2012. We investigated the clinicopathological features and prognosis of patients with DM (DM group; N = 62) and those without (non-DM group; N = 444) retrospectively. Median follow-up period was 5.2 years.

      4c3880bb027f159e801041b1021e88e8 Result

      The DM group consisted of more males, high serum CEA level, history of smoking and heart disease, vascular invasion and lymphatic permeation than the non-DM group. 5-year overall survival (OS), recurrence free survival (RFS) and disease specific survival (DSS) rate in the DM group (5-year OS rate, 80.6%; 5-year RFS rate, 77.4%; 5-year DSS rate, 91.6%) were significantly worse than those in the non-DM group (5-year OS rate, 92.0%; 5-year RFS rate, 90.6%; 5-year DSS rate 97.6%) (p = 0.001, p = 0.001 and p = 0.014; respectively). The univariate and multivariate analyses revealed that DM was an independent prognostic factor for RFS and OS (P = 0.027 and P = 0.020, respectively). Relapse in the DM group was higher than that in the non-DM group (p = 0.036). Distant metastases in the DM group (10%) were significantly more common than in the non-DM group (3%) (p = 0.015).

      8eea62084ca7e541d918e823422bd82e Conclusion

      Pathological stage IA in NSCLC patients having diabetes mellitus have a decreased survival compared with those without.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.